For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Correction to the Documents for Top Management Presentation

TOKYO, Japan (November 6, 2014) – With regard to the above, we wish to inform that there were typo errors in the document, which was filed on November 4, 2014 at 11:30, as follows.

Correction

（1）     Page20　 Progress in R&D pipeline　 CL-108  region

           Page23　 Major R&D Pipeline　 CL-108 region

              Before:　US/EU　

              After   :  US

（2）     Page20　 Progress in R&D pipeline　DS-6051  region

           Page23　 Major R&D Pipeline　 DS-6051 region

              Before:  JP　

              After   :　US

（3）     Page21　 CL-108: Hydrocodone combination　the second line

              Before:　Exclusive license for commercialization in US/EU

              After   :　Exclusive license for commercialization in US

More information regarding Daiichi Sankyo’s FY2014 Q2 financial results can be found at the following link:

https://www.daiichisankyo.com/investors/library/quarterly_result/